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Hepatoblastoma (HB) is the most common primary liver cancer of 
childhood, accounting for up to 1% of all paediatric malignancies, 
particularly in the younger child. HB is associated with congenital 
abnormalities in approximately one-third of patients, suggesting 
complex genetic and/or epigenetic factors in its pathogenesis.1,2 
In addition to an association with low birth weight, there are 
several linked genetic diseases including overgrowth syndromes such 
as Beckwith-Wiedemann syndrome, chromosomally linked conditions 
(trisomies 2, 8 and 20) and X-linked Simpson-Golabi-Behmel 
syndrome, type 1 glycogen storage diseases, Li-Fraumeni syndrome, 
familial adenomatous polyposis (FAP)3-6 and type 1 neurofibromatosis.7 
Familial recurrence of HB is extremely rare outside of associated 
adenomatous polyposis coli (APC) families,8 and a causative 
relationship between HB and  interstitial deletions of 5q21.3-q23.3 
(the APC gene region) is well known.9 Consequently, offspring of FAP 
families have a 750 - 7  500 times higher risk of developing HB.10,11 
Although 75 - 80% of FAP individuals have APC gene mutations, there 
is a group with non-typical de novo genetic variation.6 As a result, the 
screening of HB patients for APC gene variation in cases of childhood 
HB without a family FAP history remains an open discussion. It 
appears to be important to identify these high-risk individuals and 
perform long-term screening to improve their management.
We aimed to investigate HB-FAP gene associations and clinical 
implications in a South African population.
Methods
Based on available clinical data of 2 known FAP families, a local 
database of 113 FAP cases (1989 - 2010) was investigated for HB 
associations. Data were analysed for details of clinical problem, 
treatment, complications and management. Long-term morbidity and 
functional outcome were analysed to identify management difficulties.
Results
HB was evident in the offspring of 3/113 known FAP cases (2.65%). 
Case 1
A 2-year-old child re-presented after absconding half-way through a 
course of chemotherapy (cisplatinum and doxorubicin (PLADO)) for a 
stage 4 HB. Lung metastases were excised and a right hemi-hepatectomy 
of a calcified tumour was performed with removal of an additional 
localised lesion in the left lobe of the liver (Fig. 1). He has survived 
into adulthood (22 years) without further HB metastatic events. He 
presented with rectal bleeding at 14 years of age and a pedunculated 
adenomatous polyp was identified on colonoscopy and removed. He 
subsequently developed multiple rectal and colonic polyps, for which a 
total colectomy was performed. Recurrence of rectal polyps in his rectal 
stump necessitated revision of the lower rectal stump and fashioning of a 
pouch. Genetic studies identified an APC gene mutation (exon 6 codon 
232 C→T). Further investigation of family history revealed relations to a 
large well-known FAP mixed-ancestry family with >20 affected patients. 
Case 2
A mixed-ancestry male infant in a family without any FAP history 
was diagnosed with HB in the left liver lobe at 15 months of age. 
Following 4 courses of PLADO, he underwent a left hepatectomy 
with successful outcome. Six years later, the boy’s 34-year-old mother 
was diagnosed with advanced colon carcinoma and liver metastases. 
At surgery, multiple colonic polyps were also noted. The mother and 
child’s APC genes showed the same mutation (exon 15 codon 793 
C→T). The patient developed multiple adenomatous polyps, and 
was successfully treated 15 years later by total colectomy. Two other 
family members with the same genetic mutation have since been 
identified and followed up.
Background. Approximately one-third of hepatoblastoma (HB) 
patients have associated congenital abnormalities, but familial 
recurrence is rare, except in association with familial adenomatous 
polyposis (FAP). This correlation may be missed if not actively 
sought, with implications for long-term outcome and management.
Methods. We retrospectively investigated 3 families with an 
HB-familial polyposis connection, from a cohort of 113 FAP 
families (1989 - 2010). Data were analysed to assess clinical 
problem, treatment, complications and management. Long-term 
morbidity and functional outcome were analysed to identify 
management difficulties.
Results. Three FAP families (2.65%) had an HB association. In 
one case, undiagnosed FAP at the time of HB diagnosis was only 
detected 5 years later, when the mother presented with advanced 
colorectal carcinoma. A chromosome 5 APC gene mutation (exon 
15 codon 793 C→T) was then identified. In a second case, a non-
related boy presented with a stage 4 multifocal HB with lung 
metastases. Genetic studies identified an APC gene mutation 
(exon 6 codon 232 C→T). Further family investigation showed >20 
related FAP patients. A third HB-FAP association was identified in 
a known FAP family early in the study, prior to the availability of 
genetic testing. 
Conclusion. Although a rare association, a family history of 
FAP in HB patients is an important ‘hidden connection’. Germline 
variation may be outside the usual FAP gene site. Identifying 
families with unknown HB/FAP is important due to long-term 
management implications and follow-up.
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Case 3
A male infant, born to a known FAP family, was diagnosed and 
successfully treated for HB early in the study, prior to the availability of 
genetic testing. The patient never developed further features of FAP and 
there was no familial recurrence.
Discussion 
HB is a well-known embryonal tumour, with recognised genetic 
associations to several known cancer predisposition syndromes 
including FAP. Family histories are uncommon in these, with the 
exception of familial FAP,8 as shown in this study. The incidence of 
FAP in association with HB, identified in 3/113 FAP families (2.65%), 
was lower than a previous report of 8/93 (8.6%) HB families.12 
There are several lessons from this study. Firstly, although the 
genetic links between HB and FAP are well established, it is a reminder 
to clinicians of this rare, possibly hidden link. Secondly, the clinical 
identification of associated FAP in our first case benefitted the patient 
and led to the identification of a whole family at high risk of cancer. 
Thirdly, from the second case, a full history in patients with HB should 
include a family history of FAP. A timely genetic analysis for FAP in 
the child with HB would have benefitted the mother who developed 
an unsuspected metastatic carcinoma colon 6 years later on the basis 
of unsuspected FAP. Fourthly, predicting HB susceptibility on the 
basis of the site of APC mutation has proven difficult, as no significant 
correlation between the site of mutation detected in those with or 
without HB has been demonstrated.13 The nature of the HB-associated 
APC mutations, however, appears variable, as shown in 2 families 
in this study where the APC mutation sites lay outside the loss-of-
heterozygosity (LOH)-associated region for colorectal FAP (i.e. codons 
1 285 - 1 378),12,14 in keeping with previous reports.8,15
From a molecular perspective, these genetic associations may be 
a more important link than previously thought in understanding the 
oncogenesis of liver tumours such as HB. Chromosomal variations 
occur frequently in HB, having been reported in up to 88% of cases in 
a genome profiling study.16 The most likely candidate genes identified 
thus far are CTNNB1 (catenin, beta-1-catenin)17 and insulin-like 
growth factor II (IGF2) tumour suppressor at locus 11p15.18,19 In 
addition, more than 85% of HBs show accumulation of β-catenin which 
indicates an activated Wingless-type (Wnt) pathway.20 Beta-catenin 
mutations that play a key role in liver development, regeneration and 
oncogenesis, are found in 50 - 90% of HB tumours.21 However, multiple 
other deletion or point mutations and frequent gains in chromosomes 
1q, 2 (or 2q), 8, 17q, and 20 have been described in HB, as well as 
losses in chromosomes 4q and 11q, and high-grade amplifications at 
7q34, 14q11.2, and 11q22.2.4 The HB-related Beckwith-Wiedemann 
syndrome is also associated with the dysregulation and LOH of 
imprinted genes at chromosome 11p15.5.22 This subgroup is of 
considerable interest due to the location of the IGF2 and H19 genes 
within this region,16 indicating complex genetic/epigenetic associations 
of the imprinted 11p15 region in the pathogenesis of HB and other 
related tumours.23,24 
The link to FAP is important because of the high risk of developing 
HB in families with germline APC gene abnormalities. This risk is 750 - 
7 500 times higher than in the general population,10,11 as well as the risk 
of other tumours occurring in familial gene carriers. The question as to 
whether specific APC gene mutations are more likely to be associated 
with HB remains open. In both cases tested genetically in this series, 
the APC gene mutation lay outside the usual FAP site on chromosome 
5 (viz. family 1, part of a 20-strong known FAP ancestry: exon 6 codon 
232 C→T; family 2: exon 15 codon 793 C→T). The significance of this 
is unknown, but it suggests that those associated with HB may relate to 
other sites on the gene.  
Understanding the link between FAP and HB may, therefore, be of 
the utmost importance to patient evaluation and follow-up. Screening 
for APC gene mutations in infants with HB, although difficult, facilitates 
genetic counselling and an estimation of risk, owing to an autosomal 
dominant hereditary pattern.11 We agree that the presence of HB-risk 
APC mutations justifies HB screening in neonates born to gene carriers.12
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Fig. 1. Abdominal computed tomography (CT) scan showing a calcifi ed hepatoblastoma 
in segments 5, 6 and 7 of the liver following chemotherapy. 
